BEAM
Beam Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.66
+0.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 156.0M | 139.7M | 63.5M | 377.7M | 60.9M |
| Cost of Revenue | 126.5M | 22.3M | 367.6M | — | 311.6M |
| Gross Profit | 29.5M | 117.4M | (304.0M) | 377.7M | (250.7M) |
| Operating Expenses | |||||
| R&D Expense | 408.7M | 409.6M | 367.6M | 437.4M | 311.6M |
| SG&A Expense | 119.7M | 113.8M | 111.5M | 116.8M | 87.8M |
| General & Admin Expense | 119.7M | 113.8M | 111.5M | 116.8M | 87.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (120.8M) | (22.3M) | (367.6M) | — | (311.6M) |
| Total Operating Expenses | 407.6M | 501.1M | 111.5M | 554.2M | 87.8M |
| Cost and Expenses | 534.1M | 523.4M | 479.1M | 554.2M | 399.4M |
| Operating Income (EBIT) | (378.0M) | (383.7M) | (415.6M) | (176.5M) | (338.5M) |
| Non-Operating | |||||
| Interest Income | 28.3M | — | 49.1M | 46.7M | 15.3M |
| Interest Expense | 10.6M | 43.7M | — | — | — |
| Net Interest Income | 17.6M | (43.7M) | 49.1M | 46.7M | 15.3M |
| Other Non-Op Income/Expense | 292.6M | 303.7M | 38.9M | 45.3M | 52.8M |
| Non-Operating Income (excl Interest) | (295.5M) | (347.4M) | (38.9M) | (45.3M) | (52.8M) |
| EBT (Pre-Tax Income) | (85.4M) | (80.0M) | (376.7M) | (131.2M) | (285.7M) |
| Income Tax Expense | — | — | 39.0K | 1.4M | 3.4M |
| Bottom Line | |||||
| Net Income | (85.4M) | (80.0M) | (376.7M) | (132.5M) | (289.1M) |
| Earnings from Cont. Ops | (85.4M) | (80.0M) | (376.7M) | (132.5M) | (289.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (85.4M) | (80.0M) | (376.7M) | (132.5M) | (289.1M) |
| Per Share | |||||
| Basic EPS | ($0.82) | ($0.81) | ($4.58) | ($1.72) | ($4.13) |
| Diluted EPS | ($0.86) | ($0.81) | ($4.58) | ($1.72) | ($4.13) |
| Revenue Per Share | $1.50 | $1.41 | $0.77 | $4.90 | $0.87 |
| Shares | |||||
| Basic Shares Outstanding | 104.3M | 98.9M | 82.3M | 77.2M | 70.0M |
| Diluted Shares Outstanding | 104.3M | 98.9M | 82.3M | 77.2M | 70.0M |
| Profitability Metrics | |||||
| EBITDA | (60.3M) | (29.9M) | (354.8M) | (101.6M) | (271.5M) |
| D&A | 22.2M | 6.3M | 21.9M | 29.5M | 14.1M |
| EBIT | (82.5M) | (36.3M) | (376.7M) | (131.2M) | (285.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026